{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:41:36Z","timestamp":1761766896028,"version":"3.40.4"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shandong Province medical and health science and technology development plan","award":["2016WS0498"],"award-info":[{"award-number":["2016WS0498"]}]},{"name":"the Jinan clinical medical science and technology innovation plan","award":["202019188"],"award-info":[{"award-number":["202019188"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Currently, no effective prognostic model of clear cell renal cell carcinoma (ccRCC) based on immune cell infiltration has been developed. Recent studies have identified 6 immune groups (IS) in 33 solid tumors. We aimed to characterize the expression pattern of IS in ccRCC and evaluate the potential in predicting patient prognosis. The clinical information, immune subgroup, somatic mutation, copy number variation, and methylation score of patients with TCGA ccRCC cohort were downloaded from UCSC Xena for further analysis. The most dominant IS in ccRCC was the inflammatory subgroup (immune C3) (86.5%), regardless of different pathological stages, pathological grades, and genders. In the C3 subgroup, stage IV (69.1%) and grade 4 (69.9%) were the least presented. Survival analysis showed that the IS could effectively predict the overall survival (OS) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001) and disease-specific survival (DSS) (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001) of ccRCC alone, of which group C3 (OS, HR\u200a=\u200a2.3, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001; DSS, HR\u200a=\u200a2.84, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) exhibited the best prognosis. Among the most frequently mutated ccRCC genes, only VHL and PBRM1 were found to be common in the C3 group. The homologous recombination deficiency score was also lower. High heterogeneity was observed in immune cells and immunoregulatory genes of IS. Notably, CD4+ memory resting T cells were highly infiltrating, regulatory T cells (Treg) showed low infiltration, and most immunoregulatory genes (such as CX3CL1, IFNA2, TLR4, SELP, HMGB1, and TNFRSF14) were highly expressed in the C3 subgroup than in other subgroups. Enrichment analysis showed that adipogenesis, apical junction, hypoxia, IL2 STAT5 signaling, TGF-beta signaling, and UV response DN were activated, whereas E2F targets, G2M checkpoint, and MYC targets V2 were downregulated in the C3 group. Immune classification can more accurately classify ccRCC patients and predict OS and DSS. Thus, IS-based classification may be a valuable tool that enables individualized treatment of patients with ccRCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000024949","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T22:02:39Z","timestamp":1615932159000},"page":"e24949","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications"],"prefix":"10.1097","volume":"100","author":[{"given":"Qiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Human Resources, Shandong Provincial Hospital Affiliated to Shandong First Medical University"},{"name":"Department of Human Resources, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinding","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second People's Hospital of Liaocheng"},{"name":"Department of Urology, The Second Hospital of Liaocheng Affiliated to Shandong First Medical University, Liaocheng"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-5817","authenticated-orcid":false,"given":"Weiting","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Human Resources, Shandong Provincial Hospital Affiliated to Shandong First Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Shandong First Medical University"},{"name":"Department of Urology, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhu","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University"},{"name":"Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University"},{"name":"Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Liaocheng People's Hospital, Liaocheng, Shandong 250000, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University"},{"name":"Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2012.06.006","article-title":"An overview of renal cell cancer: pathology and genetics","volume":"23","author":"Moch","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"151","DOI":"10.6004\/jnccn.2015.0022","article-title":"Kidney cancer, version 3. 2015","volume":"13","author":"Motzer","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.juro.2006.09.034","article-title":"Grading systems in renal cell carcinoma","volume":"177","author":"Novara","year":"2007","journal-title":"J Urol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/path.1034","article-title":"VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma","volume":"196","author":"Schraml","year":"2002","journal-title":"J Pathol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pe\u00f1a-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yexcr.2017.12.026","article-title":"CD4+ T cells promote renal cell carcinoma proliferation via modulating YBX1","volume":"363","author":"Wang","year":"2018","journal-title":"Exp Cell Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature25144","article-title":"Effector CD8T cells dedifferentiate into long-lived memory cells","volume":"552","author":"Youngblood","year":"2017","journal-title":"Nature"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.2147\/CMAR.S172039","article-title":"Checkpoint molecule PD-1-assisted CD8 (+) T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors","volume":"10","author":"Yao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri.2016.80","article-title":"Regulatory circuits of T cell function in cancer","volume":"16","author":"Speiser","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","article-title":"Macrophage polarization in tumour progression","volume":"18","author":"Sica","year":"2008","journal-title":"Semin Cancer Biol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.21105\/joss.01627","article-title":"The UCSCXenaTools R package: a toolkit for accessing genomics data from UCSC Xena platform, from cancer multi-omics to single-cell RNA-seq","volume":"4","author":"Wang","year":"2019","journal-title":"J Open Source Softw"},{"key":"R24-20250504","first-page":"326470","article-title":"The UCSC Xena platform for public and private cancer genomics data visualization and interpretation","author":"Goldman","year":"2019","journal-title":"bioRxiv"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/2326-6066.CIR-14-0244","article-title":"Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma","volume":"3","author":"Liu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-15-0043","article-title":"Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma","volume":"3","author":"Callea","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"Mcdermott","year":"2015","journal-title":"J Clin Oncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"iv280","DOI":"10.1093\/annonc\/mdu337.2","article-title":"Immune correlates and long term follow up of a phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC)","volume":"25","author":"Mcdermott","year":"2014","journal-title":"Ann Oncol"},{"key":"R37-20250504","first-page":"2927","article-title":"Expression and prognostic significance of EP300, TP53 and BAX in clear cell renal cell carcinoma","volume":"37","author":"Godlewski","year":"2017","journal-title":"Anticancer Res"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"a026062","DOI":"10.1101\/cshperspect.a026062","article-title":"Tumor-suppressor functions of the TP53 pathway","volume":"6","author":"Aubrey","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/14737159.2015.1068122","article-title":"BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies","volume":"15","author":"Piva","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/JLB.4RI0818-311R","article-title":"Monocyte heterogeneity and functions in cancer","volume":"106","author":"Olingy","year":"2019","journal-title":"J Leukoc Biol"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fimmu.2018.00101","article-title":"Regulation of CD8 (+) T cells and antitumor immunity by Notch signaling","volume":"9","author":"Tsukumo","year":"2018","journal-title":"Front Immunol"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br J Cancer"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.smim.2019.101305","article-title":"Lymphocyte-activation gene 3 (LAG3): the next immune checkpoint receptor","volume":"42","author":"Ruffo","year":"2019","journal-title":"Semin Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:29:05Z","timestamp":1746340145000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024949","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"2020-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}